Phosphate Frustration: Treatment Options to Complement Current Therapies

Table 1

Efficacy of phosphate binders in phase 3 trials.

Reference	Number of patients	Duration of treatment (weeks)	Binders	Mean baseline phosphate levels (mg/dL)	Mean baseline phosphate levels at the end of treatment (mg/dL)	Percentage decrease in phosphate levels (%)
Emmett et al. [34]	91	2	Calcium acetate	7.3	5.9	19
			Placebo (comparator)	7.3	7.3	0
Floege et al. [35]	1041	24	Sucroferric oxyhydroxide	7.7	5.6	27
			Sevelamer (comparator)	7.4	5.3	28
Bleyer et al. [36]	84	8	Sevelamer hydrochloride	8.4	6.5	24
			Calcium acetate (comparator)	8.0	5.9	26
Mehrotra et al. [37]	126	8	Lanthanum carbonate	7.7	5.9	23
			Placebo (comparator)	7.4	7.9	(6)
Akebia therapeutics, data on file [38]	292	52	Ferric citrate	7.4	5.4	27
			Sevelamer and/or calcium acetate (comparator)	7.6	5.4	29